Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W D Figg

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|September 14, 2000
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancerE Mueller, M Smith, P Sarraf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasmsA M Senderowicz, D Headlee, S F Stinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancerR C Bergan, E Reed, C E Myers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancerN A Dawson, W D Figg, M R Cooper, et al.
Journal of Clinical Pharmacology|April 10, 1999
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosisH K Cho, R M Lush, D L Bartlett, et al.
Journal of Thrombosis and Haemostasis : JTH|July 2, 2013
The CYP2C19*17 variant is not independently associated with clopidogrel responseJ P Lewis, S H Stephens, R B Horenstein, et al.
Biotechniques|September 20, 2002
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assayT G Zogakis, N G Costouros, E A Kruger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawalN Dawson, W D Figg, O W Brawley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2000
Activity of thalidomide in AIDS-related Kaposi's sarcomaR F Little, K M Wyvill, J M Pluda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833I Chico, M H Kang, R Bergan, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
Proceedings of the National Academy of Sciences of the United States of America|September 14, 2000
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancerE Mueller, M Smith, P Sarraf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasmsA M Senderowicz, D Headlee, S F Stinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancerR C Bergan, E Reed, C E Myers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancerN A Dawson, W D Figg, M R Cooper, et al.
Journal of Clinical Pharmacology|April 10, 1999
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosisH K Cho, R M Lush, D L Bartlett, et al.
Journal of Thrombosis and Haemostasis : JTH|July 2, 2013
The CYP2C19*17 variant is not independently associated with clopidogrel responseJ P Lewis, S H Stephens, R B Horenstein, et al.
Biotechniques|September 20, 2002
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assayT G Zogakis, N G Costouros, E A Kruger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawalN Dawson, W D Figg, O W Brawley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2000
Activity of thalidomide in AIDS-related Kaposi's sarcomaR F Little, K M Wyvill, J M Pluda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833I Chico, M H Kang, R Bergan, et al.
Pageof 14